The authors propose that nitric oxide should be tested as a potential treatment for COVID-19 based on the virus's interaction with ACE2 and the renin-angiotensin system.
Answers are grounded in this paper and cite their sources.
Leaves open nitric oxide as COVID-19 therapy candidate; hypothesis-generating and requires prospective trials before consideration.
Since who characterized COVID-19 as a pandemic, all scientists and clinicians studied the viral effects on the various organs and tissues of the infected patients. The virus irreversible binding to the ACE2 in the target cell in the lungs is the first step of the viral deleterious pathway to invade the target tissues. As the virus replicates and its number increase, the ACE2 in lung type II alveolar cells become inactive. ACE2 is also located in the arterial and venous endothelial cells and arterial smooth muscle cells in most organs. ACE2 is the enzyme catalyzing the conversion of angiotensin II to angiotensin (1–7). Nitric oxide Should be tested as a potential treatment.
No takes yet. Share an insight, caveat, or question.
Elsaid et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: